Is Amgen Stock a Buy Now?

This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen (NASDAQ: AMGN) has had a better showing, but it has still substantially trailed the S&P 500.

Still, long-term investors will want to know whether the drugmaker can deliver solid results over the long run -- and one year's worth of underperformance doesn't tell us much either way. For that, let's look into what's going on with Amgen and decide whether buying the biotech's shares today is worth it.

Continue reading

Source Fool.com